Keros Therapeutics Files Routine 8-K on Jan 3 Event

TL;DR

**Keros Therapeutics filed a routine 8-K, no major news.**

AI Summary

Keros Therapeutics, Inc. filed an 8-K on January 4, 2024, reporting an event that occurred on January 3, 2024. This filing is a routine disclosure under 'Other Events' and 'Financial Statements and Exhibits,' indicating no major new developments but rather a standard update to their public record. For investors, this filing itself doesn't signal a significant change in the company's operations or financial health, but rather confirms ongoing compliance with SEC reporting requirements for KROS stock.

Why It Matters

This filing is a standard compliance update, not indicating any material change in Keros Therapeutics' business or financial condition. It primarily serves to keep the public record current.

Risk Assessment

Risk Level: low — This 8-K is a procedural filing with no specific adverse or positive news, thus posing low risk.

Analyst Insight

Investors should note this is a routine compliance filing and does not contain new material information that would typically warrant an immediate investment action. It's a confirmation of ongoing regulatory adherence.

Key Players & Entities

• Keros Therapeutics, Inc. (company) — the registrant filing the 8-K
• The Nasdaq Stock Market LLC (company) — the exchange where Keros Therapeutics' common stock is registered
• 001-39264 (other) — Commission File Number for Keros Therapeutics
• 81-1173868 (other) — I.R.S. Employer Identification Number for Keros Therapeutics

FAQ

Key Financial Figures

• $0.0001 — ge on which registered Common Stock, $0.0001 par value per share KROS The Nasdaq Sto
• $40.00 — Common Stock"), at an offering price of $40.00 per share, less underwriting discounts
• $131.2 m — from the offering will be approximately $131.2 million, after deducting underwriting dis

Filing Documents

• kros-20240103.htm (8-K) — 41KB
• exhibit11-8xk2024pricing.htm (EX-1.1) — 342KB
• exhibit51january2024.htm (EX-5.1) — 11KB
• cooleylogo.jpg (GRAPHIC) — 100KB
• 0001664710-24-000006.txt ( ) — 733KB
• kros-20240103.xsd (EX-101.SCH) — 2KB
• kros-20240103_lab.xml (EX-101.LAB) — 25KB
• kros-20240103_pre.xml (EX-101.PRE) — 13KB
• kros-20240103_htm.xml (XML) — 3KB

01. Other Events

Item 8.01. Other Events. On January 3, 2024, Keros Therapeutics, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Goldman Sachs & Co. LLC, Leerink Partners LLC, Piper Sandler & Co. and Truist Securities, Inc., as representatives of the several underwriters (collectively, the "Underwriters"), in connection with the offering, issuance and sale by the Company of 3,500,000 shares of the Company's common stock, $0.0001 par value per share (the "Common Stock"), at an offering price of $40.00 per share, less underwriting discounts and commissions, pursuant to an effective shelf registration statement on Form S-3 (Registration No. 333-255724). A prospectus supplement relating to the offer and sale of the shares was filed with the Securities and Exchange Commission. The closing of the offering is expected to occur on January 8, 2024, subject to the satisfaction of customary closing conditions. The Company estimates the net proceeds from the offering will be approximately $131.2 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The Company intends to use the net proceeds of the offering, together with its existing cash and cash equivalents, to continue to advance the development of KER-050 in two Phase 2 clinical trials, one in patients with myelodysplastic syndromes and one in patients with myelofibrosis, and to initiate one Phase 3 clinical trial; to continue the development of KER-012 in two Phase 2 clinical trials, one in patients with pulmonary arterial hypertension and one in patients with chronic heart failure with preserved ejection fraction and in such patients with reduced ejection fraction; to advance the development of KER-065, including the completion of the ongoing Phase 1 clinical trial; and to continue the development of its preclinical pipeline. The Company intends to use the remainder to fund other research and development activities, incl

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 1.1 Underwriting Agreement, dated January 3 , 2024, by and among the Company, Goldman Sachs & Co. LLC, Leerink Partners LLC, Piper Sandler & Co. and Truist Securities, Inc . 5.1 Opinion of Cooley LLP. 23.1 Consent of Cooley LLP (included in Exhibit 5.1) 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KEROS THERAPEUTICS, INC. By: /s/ Jasbir Seehra Jasbir Seehra, Ph.D. Chief Executive Officer Dated: January 4, 2024

View Full Filing

View this 8-K filing on SEC EDGAR